Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer

Radiation Therapy Promotes Hepatocellular Carcinoma Immune Cloaking via PD-L1 Upregulation Induced by cGAS-STING Activation

(2022) Shi-Suo Du et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Hallmarks of Cancer: New Dimensions

(2022) Douglas Hanahan   Cancer Discovery

Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)

(2022) Inna M. Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer

(2022) Zhan Shi et al.   Frontiers in Oncology

Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial

(2022) Kim A Reiss et al.   LANCET ONCOLOGY

Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination

(2021) Jiali Yu et al.   NATURE MEDICINE

Understanding and treating the inflammatory adverse events of cancer immunotherapy

(2021) Michael Dougan et al.   CELL

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

(2021) Cristina Valero et al.   Nature Communications

Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors

(2021) Jessica J. Waninger et al.   JAMA Network Open

The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives

(2021) Jamal Majidpoor et al.   CLINICAL IMMUNOLOGY

Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy

(2021) Xiaona Fan et al.   Frontiers in Cell and Developmental Biology

Estimated Projection of US Cancer Incidence and Death to 2040

(2021) Lola Rahib et al.   JAMA Network Open

Pancreatic Cancer

(2021) Wungki Park et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial

(2021) Xiaofei Zhu et al.   LANCET ONCOLOGY

Targeting the IGF-axis potentiates immunotherapy for pancreatic ductal adenocarcinoma liver metastases by altering the immunosuppressive microenvironment.

(2021) Masakazu Hashimoto et al.   MOLECULAR CANCER THERAPEUTICS

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

(2021) Lars Ny et al.   Nature Communications

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

(2021) G. Fornarini et al.   ESMO Open

Radiotherapy and immunotherapy for cancer: From "systemic" to "multi-site"

(2020) Ainhoa Arina et al.   CLINICAL CANCER RESEARCH

Lactate dehydrogenase: a marker of diminished antitumor immunity

(2020) Sandra Van Wilpe et al.   OncoImmunology

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

(2020) Lihong Peng et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications

(2020) Claudio Luchini et al.   GUT

Lymphocyte‐monocyte ratio (LMR) can predict bendamustine therapeutic efficacy in low‐grade B‐cell lymphoma

(2020) Joji Shimono et al.   International Journal of Laboratory Hematology

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

(2020) Bruno Bockorny et al.   NATURE MEDICINE

Challenges and Opportunities for Pancreatic Cancer Immunotherapy

(2020) Adham S. Bear et al.   CANCER CELL

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

(2020) Aurélien Marabelle et al.   LANCET ONCOLOGY

Inflammation and Cancer: Triggers, Mechanisms, and Consequences

(2019) Florian R. Greten et al.   IMMUNITY

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

(2019) Eileen M. O’Reilly et al.   JAMA Oncology

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Aurelien Marabelle et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunological impact of cell death signaling driven by radiation on the tumor microenvironment

(2019) Maria Esperanza Rodriguez-Ruiz et al.   NATURE IMMUNOLOGY

Colorectal cancer liver metastases – a population-based study on incidence, management and survival

(2018) Jennie Engstrand et al.   BMC CANCER

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

(2018) Laura Mezquita et al.   JAMA Oncology

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

(2015) Christina Twyman-Saint Victor et al.   NATURE

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen

(2014) A. B. Sharabi et al.   Cancer Immunology Research

Tumor-Associated Neutrophils: New Targets for Cancer Therapy

(2011) A. D. Gregory et al.   CANCER RESEARCH